Andrei Anghel

Prof. Dr. Andrei Anghel


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2022 in Medicina
Verified
Journal Article
Open access
PDF file
MSMiruna Samfireag
Miruna Samfireag
PCPotre Cristina
Potre Cristina
OPOvidiu Potre
Ovidiu Potre
Raluca TudorRaluca Tudor
Raluca Tudor
THTeodora Hoinoiu
Teodora Hoinoiu
AAAndrei Anghel
Andrei Anghel
Thrombophilia is a genetic predisposition to hypercoagulable states caused by acquired haemostasis conditions; pregnancy causes the haemostatic system to become hypercoagulable, which grows throughout the pregnancy and peaks around delivery. Genetic testing for thrombophilic gene mutations is evaluated using different methodologies of real-time polymerase chain reaction and DNA microarrays of specific genes. Adapting the general care of the pregnant woman to the particularities caused by thrombophilia is an important component, so screening is preferred to assess the degree of genetic damage that manifests itself as a risk of thrombosis. The major goal of this narrative review was to quantitatively evaluate the literature data on the specific care of pregnant women with thrombophilia that are at risk of developing unplanned miscarriages.

1 August 2015 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
MCMaria Sala Cirtog
Maria Sala Cirtog
CMCatalin Marian
Catalin Marian
AAAndrei Anghel
Andrei Anghel

1 January 2010 in Neoplasma
Verified
Journal Article
Closed access
AAAndrei Anghel
Andrei Anghel
MRM. Raica
M. Raica
DND. Narita
D. Narita
ESEdward Seclaman
Edward Seclaman
TNT. Nicola
T. Nicola
EPEmanuel Popovici
Emanuel Popovici
Estrogen receptor alpha polymorphisms: correlation with clinicopathological parameters in breast cancer

13 September 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
LMLiana Maries
Liana Maries
CMCatalin Marian
Catalin Marian
R(Raluca Coifan (Șoșdean)
Raluca Coifan (Șoșdean)
FGFlavia Goanta
Flavia Goanta
ISIoan-Ovidiu Sirbu
Ioan-Ovidiu Sirbu
AAAndrei Anghel
Andrei Anghel
Myocardial infarction (MI) is one of the most frequent cardiac emergencies, with significant potential for mortality. One of the major challenges of the post-MI healing response is that replacement fibrosis could lead to left ventricular remodeling (LVR) and heart failure (HF). This process involves canonical and non-canonical transforming growth factor-beta (TGF-β) signaling pathways translating into an intricate activation of cardiac fibroblasts and disproportionate collagen synthesis. Accumulating evidence has indicated that microRNAs (miRNAs) significantly contribute to the modulation of these signaling pathways. This review summarizes the recent updates regarding the molecular mechanisms underlying the role of the over 30 miRNAs involved in post-MI LVR. In addition, we compare the contradictory roles of several multifunctional miRNAs and highlight their potential use in pressure overload and ischemia-induced fibrosis. Finally, we discuss their attractive role as prognostic biomarkers for HF, highlighting the most relevant human trials involving these miRNAs.

1 August 2011 in Current Neurovascular Research
Verified
Journal Article
Closed access
PDF file
AAAndrei Anghel
Andrei Anghel
GTGeorgel Taranu
Georgel Taranu
ESEdward Seclaman
Edward Seclaman
ARAndreea Luciana Rata
Andreea Luciana Rata
LTLiviu Athos Tamas
Liviu Athos Tamas
Aurel Popa-WagnerAurel Popa-Wagner
Aurel Popa-Wagner
The present clinical trial analyzed the safety of gene therapy using plasmidial constructs expressing vascular endothelial and hepatocyte growth factors in patients with critical limb ischemia. The study included 43 patients: 29 in the treatment group and 14 allocated to the placebo group. The primary end points were the rate of major amputations and the clinical safety of the method. Secondary end points were improvement of pain at rest, walking ability and the ankle/brachial pressure index. The overall major amputation rate was 31.04% in the treatment group and 71.42% in the placebo group (p=0.029). Pain at rest was improved in 65% of patients in the gene therapy group and in 7% in the placebo group (p=0.0006). There were no significant adverse effects in the treatment group. Conclusion: Gene therapy with vascular endothelial and hepatocyte growth factors is therapeutically safe and reduces the rate of major amputations and relieves pain at rest in patients with critical limb ischemia.

24 February 2016 in Restorative Neurology and Neuroscience
Verified
Journal Article
Closed access
PDF file
RSRaluca Elena Sandu
Raluca Elena Sandu
AUAdriana Uzoni
Adriana Uzoni
OCOvidiu Ciobanu
Ovidiu Ciobanu
Mihai MoldovanMihai Moldovan
Mihai Moldovan
AAAndrei Anghel
Andrei Anghel
Aurel Popa-WagnerAurel Popa-Wagner
Aurel Popa-Wagner
Purpose: In aged humans, stroke is a major cause of disability for which no neuroprotective measures are available. In animal studies of focal ischemia, short-term hypothermia often reduces infarct size. Nevertheless, efficient neuroprotection requires long-term, regulated lowering of whole body temperature. Previously, we reported that post-stroke exposure to hydrogen sulfide (H2S) effectively lowers whole body temperature and confers neuroprotection in aged animals. Methods: In the present study using behavioral tests, MRI, telemetrical EEG, BP and temperature recordings, RT-PCR and immunofluorescence, we assessed infarct size, vascular density, neurogenesis and as well as the expression of genes coding for proteasomal proteins as well as in post-stroke aged Sprague-Dawley rats exposed to H2S- induced hypothermia. Results: Two days exposure to mild hypothermia diminishes the expression of several genes involved in protein degradation, thereby leading to better preservation of infarcted tissue. Further, hypothermia increased the density of newly formed blood vessels in the peri-lesional cortex did not enhance neurogenesis in the infarcted area of aged rats. Likewise, there was improved recovery of fine vestibulomotor function and asymmetric sensorimotor deficit. Conclusion: Long-term hypothermia may be a viable clinical approach by simultaneously targeting multiple processes including better tissue preservation, enhanced vascular density and improved behavioral performance.